Published in Br J Pharmacol on May 01, 1986
The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs. Br J Pharmacol (1990) 0.88
Nimodipine-induced changes in the distribution of carotid blood flow and cardiac output in pentobarbitone-anaesthetized pigs. Br J Pharmacol (1986) 0.86
Haemodynamic profile of the potassium channel activator EMD 52692 in anaesthetized pigs. Br J Pharmacol (1990) 0.81
Nimodipine has no effect on the cerebral circulation in conscious pigs, despite an increase in cardiac output. Br J Pharmacol (1990) 0.80
Myocardial drug distribution generated from local epicardial application: potential impact of cardiac capillary perfusion in a swine model using epinephrine. J Control Release (2014) 0.76
Adverse interaction between nifedipine and beta-blockade. Br Med J (1980) 1.60
Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552). Arzneimittelforschung (1980) 1.57
Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem. Br J Pharmacol (1983) 1.48
Nifedipine and beta-blockade as a cause of cardiac failure. Br Med J (Clin Res Ed) (1982) 1.41
Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed (1980) 1.29
5-Carboxamide tryptamine, a compound with high affinity for 5-hydroxytryptamine1 binding sites, dilates arterioles and constricts arteriovenous anastomoses. Br J Pharmacol (1985) 1.25
Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay k 5552), a new dihydropyridine calcium antagonist. J Pharmacol Exp Ther (1981) 1.09
[Further studies on the myogenic nature of autoregulation of kidney blood circulation; suppression of autoregulation by musculotropic substances and the pressure passive behavior of glomerulus filtrate]. Pflugers Arch (1959) 1.01
Differences between the effects of calcium antagonists in the pithed rat preparation. J Cardiovasc Pharmacol (1983) 0.97
Reflex chronotropic and inotropic effects of calcium channel-blocking agents in conscious dogs. Diltiazem, verapamil, and nifedipine compared. Circ Res (1983) 0.97
Hemodynamic effects of nisoldipine in chronic congestive heart failure. Arzneimittelforschung (1983) 0.96
Effects of the calcium antagonist PY 108-068 on myocardial tissues in vitro and on reflex tachycardia in vivo. J Cardiovasc Pharmacol (1983) 0.94
Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation (1982) 0.94
Acute systemic and regional hemodynamic effects of felodipine, a new calcium antagonist, in conscious renal hypertensive rabbits. J Cardiovasc Pharmacol (1984) 0.91
Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow and oxygen supply in angina pectoris. Am J Cardiol (1984) 0.86
Effects of nifedipine on coronary and systemic hemodynamics in the conscious dog. Arzneimittelforschung (1979) 0.86
Tissue blood flow changes induced by propranolol infusion in conscious normotensive and renal hypertensive rabbits. Arch Int Pharmacodyn Ther (1983) 0.85
Effects of a calcium-channel antagonist on large and small coronary arteries in conscious dogs. Circulation (1982) 0.85
Hemodynamic effects of the new vasodilator drug Bay k 5552 in man. Arzneimittelforschung (1980) 0.84
Effects of nisoldipine on cardiocirculatory dynamics and cardiac output distribution in conscious rats at rest and during treadmill exercise. J Pharmacol Exp Ther (1985) 0.82
Interaction of atenolol with the systemic and regional hemodynamic effects of hydralazine in conscious renal hypertensive rabbits. J Pharmacol Exp Ther (1984) 0.82
Nifedipine and myocardial performance in the presence and absence of beta-blockade with propranolol. Arch Int Pharmacodyn Ther (1983) 0.81
Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: alterations in baroreflex sensitivity. J Pharmacol Exp Ther (1984) 0.81
Is nisoldipine capable of reducing left ventricular preload? Eur J Pharmacol (1984) 0.80
Calcium-entry blockade, beta-adrenergic blockade and the reflex control of circulation. Circulation (1982) 0.80
Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade. J Pharmacol Exp Ther (1984) 0.80
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev (1994) 7.11
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology (1986) 5.83
Myocardial protection by brief ischemia in noncardiac tissue. Circulation (1996) 2.91
Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation (1985) 2.61
Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation (2001) 2.28
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation (1995) 2.25
Recommendations on stent manufacture, implantation and utilization. Study Group of the Working Group on Coronary Circulation. Eur Heart J (1997) 2.05
Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Eur J Pharmacol (1974) 2.04
Thrombolytic therapy for acute myocardial infarction: quo vadis? A review of the recent literature. Eur Heart J (1982) 2.00
Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension (1994) 1.87
Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation (1988) 1.74
Emergency coronary angioplasty in refractory unstable angina. N Engl J Med (1985) 1.73
Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 1.54
Ergotamine in the acute treatment of migraine: a review and European consensus. Brain (2000) 1.52
Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension. Eur Heart J (1996) 1.52
The effects of mianserin hydrochloride on the vascular responses evoked by 5-hydroxytryptamine and related vasoactive substances. Eur J Pharmacol (1971) 1.49
Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology (2000) 1.47
Left ventricular performance, regional blood flow, wall motion, and lactate metabolism during transluminal angioplasty. Circulation (1984) 1.46
Ischaemic preconditioning by partial occlusion without intermittent reperfusion. Cardiovasc Res (1994) 1.44
Acute coronary artery obstruction in myocardial infarction: overview of thrombolytic therapy. J Am Coll Cardiol (1987) 1.43
Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol (1998) 1.42
Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin beta 2 and thromboxane prostanoid receptors. Am J Respir Crit Care Med (1994) 1.41
Invasive coronary imaging in animal models of atherosclerosis. Neth Heart J (2011) 1.40
Echocardiographic diagnosis of pseudoaneurysm of the left ventricle. Circulation (1975) 1.38
Coronary side-effect potential of current and prospective antimigraine drugs. Circulation (1998) 1.36
Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int (2001) 1.36
Mediation of 5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-HT4 receptor. Br J Pharmacol (1990) 1.31
Coronary artery dimensions from cineangiograms methodology and validation of a computer-assisted analysis procedure. IEEE Trans Med Imaging (1984) 1.31
Determination of left ventricular wall thickness by angiocardiography. Am Heart J (1969) 1.30
Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed (1980) 1.29
Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation (1998) 1.27
5-Carboxamide tryptamine, a compound with high affinity for 5-hydroxytryptamine1 binding sites, dilates arterioles and constricts arteriovenous anastomoses. Br J Pharmacol (1985) 1.25
5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor. Br J Pharmacol (1988) 1.25
Alterations in myofilament function contribute to left ventricular dysfunction in pigs early after myocardial infarction. Circ Res (2004) 1.24
On serotonin and migraine: a clinical and pharmacological review. Cephalalgia (1993) 1.23
The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol (1978) 1.22
Myocardial force-velocity relationships in clinical heart disease. Circulation (1970) 1.19
Resolution problems in echocardiology: a source of interpretation errors. Am J Cardiol (1976) 1.19
Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation (1998) 1.16
Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol (1998) 1.16
Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J (1983) 1.15
Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol (1982) 1.15
Mechanism of selective cardiac vagolytic action of pancuronium bromide. Specific blockade of cardiac muscarinic receptors. Eur J Pharmacol (1970) 1.15
Intracardiac right-to-left shunts demonstrated by two-dimensional echocardiography after peripheral vein injection. Br Heart J (1979) 1.15
Characterization of putative 5-HT7 receptors mediating tachycardia in the cat. Br J Pharmacol (1997) 1.14
Oxidative epithelial damage produces hyperresponsiveness of human peripheral airways. Am J Respir Crit Care Med (1994) 1.14
Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension (1997) 1.14
Proto-oncogene expression in porcine myocardium subjected to ischemia and reperfusion. Circ Res (1992) 1.13
Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension (1997) 1.13
Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine--studies in an experimental model for migraine. Headache (1974) 1.12
Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology (1992) 1.10
Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation of tachycardia by 5-HT1-like receptors. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.10
Ventricular free wall rupture: sudden, subacute, slow, sealed and stabilized varieties. Eur Heart J (1984) 1.10
Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia. Am J Cardiol (1981) 1.09
Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. Eur Heart J (1985) 1.09
Fixed subaortic stenosis. Value of echocardiography for diagnosis and differentiation between various types. Br Heart J (1979) 1.07
Transmission of ultrasonic contrast through the lungs. Ultrasound Med Biol (1981) 1.07
Regional cardioplegia and cardioprotection during transluminal angioplasty, which role for nifedipine? Eur Heart J (1983) 1.07
Has melatonin a future as a cardioprotective agent? Cardiovasc Drugs Ther (2001) 1.07
Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart (2000) 1.06
Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol (1995) 1.06
Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol (1986) 1.06
Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in the ischemic porcine heart. J Cardiovasc Pharmacol (1980) 1.05
Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig. Br J Pharmacol (1991) 1.05
Maxillary reconstruction: functional and aesthetic considerations. Plast Reconstr Surg (1999) 1.05
The ARTS study (Arterial Revascularization Therapies Study). Semin Interv Cardiol (1999) 1.05
Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model. Eur Heart J (1998) 1.04
Coronary angioplasty of the unstable angina related vessel in patients with multivessel disease. Eur Heart J (1986) 1.04
Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo. Circulation (2000) 1.04
Estimation of the probability of exercise-induced ischemia by quantitative ECG analysis. Circulation (1977) 1.04
Is transluminal coronary angioplasty mandatory after successful thrombolysis? Quantitative coronary angiographic study. Br Heart J (1983) 1.03
Regional wall motion from radiopaque markers after intravenous and intracoronary injections of nifedipine. Circulation (1981) 1.03
The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci (1994) 1.03
Coronary recanalization in acute myocardial infarction: immediate results and potential risks. Eur Heart J (1982) 1.03
Transmural bioenergetic responses of normal myocardium to high workstates. Am J Physiol (1995) 1.03
Animal models in the study of myocardial ischaemia and ischaemic syndromes. Cardiovasc Res (1998) 1.02
Cardiorespiratory and metabolic effects of profound hypothermia. Crit Care Med (1978) 1.01
Prediction of left heart filling pressure and its sequential change in acute myocardial infarction from the terminal force of the P wave. Br Heart J (1973) 1.01
Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology (1980) 1.01
Effect of left ventricular hypertrophy secondary to chronic pressure overload on transmural myocardial 2-deoxyglucose uptake. A 31P NMR spectroscopic study. Circulation (1995) 1.01
Clinical course after attempted thrombolysis in myocardial infarction. Results of pilot studies and preliminary data from a randomized trial. Eur Heart J (1982) 1.01
Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations. J Am Coll Cardiol (1986) 1.00
Tissue blood flow and localization of arteriovenous anastomoses in pigs with microspheres of four different sizes. Pflugers Arch (1985) 1.00
N-(3-acetylaminophenyl)piperazine hydrochloride (BEA 1654), a putative 5-HT1 agonist, causes constriction of arteriovenous anastomoses and dilatation of arterioles. Eur J Pharmacol (1985) 1.00
ATP-sensitive K+ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. Circ Res (1998) 1.00